
ARTELO BIOSCIENCES, INC.
94
Recent developments include clinical progress for ART26.12 with upcoming presentation of first clinical results, expanded patent coverage for ART27.13 following obesity study findings, positive ART27.13 data in neuropathy models, and corporate actions such as a reverse stock split.
- Artelo Biosciences announced it will feature first clinical results for ART26.12 at BIO-Europe, highlighting progress in its development as a non-opioid treatment for pain [N1].
- The company expanded patent coverage for ART27.13 after findings in obesity studies, strengthening intellectual property protection [N2].
- ART27.13 demonstrated weight loss efficacy comparable to semaglutide in an obesity model, supporting its therapeutic potential [N3].
- Artelo secured Japanese patent allowance for ART27.13 commercial formulation, enhancing global patent estate [N5].
- Positive ART27.13 data were reported in a neuropathy model, indicating potential broader applications [N6].
- The company announced a 1-for-9 reverse stock split to comply with listing requirements [N4].
Artelo Biosciences, Inc. focuses on developing and commercializing pharmaceuticals that modulate lipid-signaling pathways, particularly the endocannabinoid system (ECS). The ECS is a biochemical communication network involving cannabinoid receptors CB1 and CB2, which regulate various physiological functions. Artelo's pipeline includes three main product candidates: ART27.13, a synthetic dual cannabinoid GPCR agonist targeting cancer-related anorexia cachexia syndrome; ART26.12, a small molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5) with potential applications in neuropathy, cancer, pain, dermatologic, and anxiety disorders; and ART12.11, a proprietary synthetic cannabidiol (CBD) cocrystal composition aimed at anxiety and related indications. The company holds multiple patents and licenses for these candidates and conducts clinical trials in accordance with regulatory standards. Artelo's strategy includes internal development and potential partnerships to maximize value.
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system. Its pipeline includes ART27.13 for cancer-related anorexia in Phase 1b/2a trials, ART26.12, a FABP5 inhibitor in Phase 1 trials for chemotherapy-induced peripheral neuropathy and other indications, and ART12.11, a proprietary synthetic CBD cocrystal in preclinical development. The company holds multiple patents worldwide and has reported positive clinical and preclinical data. As of September 30, 2026, Artelo had $4.2 million in cash and equivalents, a strong liquidity position, and reported a net loss of $1.77 million for the quarter. Recent news highlights include clinical progress, patent expansions, and corporate actions such as a reverse stock split. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Artelo's clinical-stage pipeline addresses significant unmet medical needs in cancer-related anorexia, chemotherapy-induced peripheral neuropathy, and anxiety disorders. Positive interim clinical data for ART27.13 showing weight gain benefits and favorable safety, along with ART26.12's successful Phase 1 safety and pharmacokinetic profile, demonstrate potential therapeutic value. The company's broad patent estate and expanding intellectual property coverage support exclusivity. Continued clinical progress, regulatory approvals, and potential partnerships could enhance the company's ability to commercialize novel lipid-signaling modulators.
Artelo faces risks typical of clinical-stage biopharmaceutical companies, including the uncertainty of clinical trial outcomes, regulatory approvals, and market acceptance. The company reported net losses and relies on capital raises to fund operations, with liquidity dependent on successful financing. Maintaining Nasdaq listing requirements poses a risk given the low market value of publicly held shares. Competition in cannabinoid and lipid-signaling therapeutics is intense, and the complexity of ECS biology may challenge drug development. Patent expirations and challenges could affect exclusivity. Failure to advance clinical programs or secure partnerships could impact business viability.
Artelo Biosciences' moat is based on its proprietary lipid-signaling modulation platform targeting the endocannabinoid system and FABP5, supported by a broad and growing patent portfolio covering composition of matter and utility claims worldwide. The company has in-licensed promising clinical-stage assets such as ART27.13 and developed internally novel compounds like ART12.11 with improved pharmaceutical properties. Its clinical progress with positive safety and efficacy signals in unmet medical needs such as cancer anorexia and chemotherapy-induced neuropathy adds to its competitive positioning. The specialized scientific focus on lipid signaling and ECS modulation, combined with intellectual property protection and clinical data, creates barriers to entry for competitors.
• Nasdaq Listing Risk: The market value of publicly held shares is close to the minimum required for continued Nasdaq listing. Failure to maintain this or other listing requirements could lead to delisting, reducing liquidity and capital raising ability.
• Clinical Development Risk: Clinical trials for ART27.13, ART26.12, and ART12.11 may not demonstrate safety or efficacy sufficient for regulatory approval or commercialization.
• Financial Risk: The company has reported net losses and depends on capital raises to fund operations. Insufficient funding could delay or halt development programs.
• Regulatory Risk: Obtaining marketing authorization from regulatory authorities is uncertain and may involve delays or additional requirements.
• Competitive Risk: The biopharmaceutical sector targeting ECS and lipid signaling is competitive, with potential for competing therapies to limit market opportunities.
Business trends: Continued clinical development of ART27.13 and ART26.12 with expanding patent protection and exploration of multiple therapeutic indications.
Execution milestones: Presentation of clinical data at industry conferences, enrollment and progression in Phase 2 trials, and maintenance of regulatory compliance including Nasdaq listing.
Key risks: Clinical trial uncertainties, regulatory approval challenges, financial sustainability, and risks related to maintaining Nasdaq listing requirements.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics targeting lipid-signaling modulation pathways, including the endocannabinoid system (ECS).
- The company is incorporated in Nevada and based in San Diego, California.
- Artelo's product pipeline includes ART27.13, a synthetic dual cannabinoid GPCR agonist targeting CB1 and CB2 peripheral receptors, developed initially by AstraZeneca and licensed exclusively through NEOMED.
- ART27.13 is in Phase 1b/2a clinical trials for cancer-related anorexia cachexia syndrome, with interim Phase 2a data showing mean weight gain of over 6% in treated patients versus weight loss in placebo, and a favorable safety profile.
- ART26.12 is a small molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5), with potential applications in chemotherapy-induced peripheral neuropathy (CIPN), cancer, dermatologic conditions like psoriasis, pain, inflammation, and anxiety disorders including PTSD.
- ART26.12 received FDA clearance for IND in July 2024 and completed Phase 1 single ascending dose trial in healthy volunteers with positive safety and pharmacokinetic results.
- ART12.11 is a proprietary synthetic cannabidiol (CBD) cocrystal composition with improved pharmacokinetics and bioavailability, targeting anxiety, depression, PTSD, and other indications; it is wholly owned by Artelo.
- The company holds multiple patents and patent applications for its product candidates: ART27.13 has issued U.S. and foreign patents with composition of matter claims; ART26.12 has multiple issued patents and pending applications worldwide; ART12.11 has issued patents in the U.S. and foreign jurisdictions with composition and use claims.
- Artelo's business strategy focuses on developing and commercializing pharmaceuticals that modulate lipid signaling and the ECS, aiming to address unmet medical needs in cancer, pain, inflammation, neurological diseases, and anxiety disorders.
- The company has conducted multiple private placements and public offerings to fund clinical trials and operations.
- Recent news highlights include clinical progress for ART26.12 with first clinical results to be featured at BIO-Europe, expanded patent coverage for ART27.13 following obesity study findings, positive ART27.13 data in neuropathy models, and enrollment of patients in Phase 2 glaucoma studies for ART27.13.
- The company announced a 1-for-9 reverse stock split in August 2026.
- As of September 30, 2026, Artelo reported cash and cash equivalents of $4.2 million, current assets of $4.6 million, current liabilities of $0.44 million, resulting in a current ratio of 10.47 and a cash ratio of 4.54, indicating strong liquidity.
- Net income for the quarter ended September 30, 2026, was a loss of $1.77 million, with diluted EPS of -3.19 USD per share.
- The company is listed on Nasdaq Capital Market and faces risks related to maintaining minimum market value and listing requirements.
- The ECS is a biochemical communication system involving cannabinoid receptors CB1 and CB2, which Artelo targets with synthetic molecules.
- FABP5 inhibitors like ART26.12 are designed to modulate lipid signaling and have shown preclinical activity in pain, cancer, and anxiety disorder models.
- ART27.13 demonstrated clinically meaningful increases in body weight without CNS side effects in early studies.
- ART26.12 Phase 1 study showed mild, transient adverse events with no drug-related safety signals.
- ART12.11's single crystal form aims to improve stability, solubility, and bioavailability compared to other CBD forms.
- Artelo plans to develop its candidates according to regulated drug development standards and may seek partnerships to maximize value.
- The company has a broad patent estate covering its product candidates and related chemistries worldwide.
Generated 2026-11-12
- S1 | 2026-02-24 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-10-07 | www.nasdaq.com | Artelo Biosciences To Feature First Clinical Results For ART26.12 At BIO-Europe | https://www.nasdaq.com/articles/artelo-biosciences-feature-first-clinical-results-art2612-bio-europe
- N2 | 2026-09-23 | www.nasdaq.com | Artelo Expands ART27.13 Patent Coverage After Obesity Study Findings | https://www.nasdaq.com/articles/artelo-expands-art2713-patent-coverage-after-obesity-study-findings
- N3 | 2026-09-16 | www.nasdaq.com | Artelo Reports ART27.13 Matches Semaglutide Weight Loss In Obesity Model | https://www.nasdaq.com/articles/artelo-reports-art2713-matches-semaglutide-weight-loss-obesity-model
- N4 | 2026-08-27 | www.nasdaq.com | Artelo Biosciences Announces 1-for-9 Reverse Stock Split | https://www.nasdaq.com/articles/artelo-biosciences-announces-1-9-reverse-stock-split
- N5 | 2026-08-20 | www.nasdaq.com | Artelo Biosciences Secures Japanese Patent Allowance For ART27.13 Commercial Formulation | https://www.nasdaq.com/articles/artelo-biosciences-secures-japanese-patent-allowance-art2713-commercial-formulation
- N6 | 2026-07-13 | www.nasdaq.com | Artelo Biosciences Reports Positive ART27.13 Data In Neuropathy Model | https://www.nasdaq.com/articles/artelo-biosciences-reports-positive-art2713-data-neuropathy-model
- N7 | 2025-07-09 | www.nasdaq.com | Artelo Biosciences Presents Preclinical Data on ART26.12 as Potential Non-Opioid Treatment for Osteoarthritis Pain at ICRS Symposium | https://www.nasdaq.com/articles/artelo-biosciences-presents-preclinical-data-art2612-potential-non-opioid-treatment
- N8 | 2025-06-30 | www.nasdaq.com | Artelo Announces Positive Phase 1 Data Of Non-Opioid Analgesic Candidate For Persistent Pain | https://www.nasdaq.com/articles/artelo-announces-positive-phase-1-data-non-opioid-analgesic-candidate-persistent-pain
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


